Jefferies initiates Braveheart Bio stock with buy on heart drug potential

Jefferies has given Braveheart Bio (NASDAQ: BRVE) a buy rating and set a price target of $48.00 per share, indicating a potential 75% increase from its current valuation of $27.44. The company's market capitalization stands at $1.76 billion, and its lead drug, BHB-1893, is an oral cardiac myosin inhibitor that Hengrui licensed to Braveheart in September 2025.

BHB-1893 shows promise in treating hypertrophic cardiomyopathy, a condition affecting over 700,000 patients in the U.S., with roughly an equal split between obstructive and non-obstructive forms. Two Phase II datasets from the Chinese partner Hengrui suggest that BHB-1893 could stand out in terms of dosing convenience, safety, and efficacy for both obstructive and non-obstructive hypertrophic cardiomyopathy. The market opportunity for this drug is estimated to be between $4 billion and $5 billion or more.

Although Braveheart Bio is not yet profitable, with losses of $2.63 per share over the past year, its strong financial flexibility is evident through a current ratio of 8.11. Multiple data points are expected in 2026 and 2027 that could further solidify BHB-1893's potential superiority, including Phase III data for obstructive hypertrophic cardiomyopathy in the first half of 2027 from China, long-term Phase II data for non-obstructive hypertrophic cardiomyopathy in the first half of 2027 from China, and interim Phase III data for obstructive hypertrophic cardiomyopathy in the second half of 2027 globally.

In comparison to other cardiac myosin inhibitors like Bristol Myers Squibb's Camzyos and Cytokinetics' Myqorzo, BHB-1893 could offer better safety, such as a lower risk of heart-failure in patients with reduced left ventricular ejection fraction, enhanced ease of use due to simpler symptom-based titration, fewer echocardiograms required, and faster-acting, superior efficacy.

Braveheart Bio completed a $382.5 million initial public offering in the U.S., surpassing market expectations for pricing and reflecting strong investor interest, primarily from mutual funds and healthcare-focused investors. The company's market value reached $2.13 billion following its trading debut. Stifel and Goldman Sachs have also initiated coverage of Braveheart Bio with buy ratings and price targets of $45.00 and $48.00, respectively, emphasizing confidence in the company's drug candidate, BHB-1893, for hypertrophic cardiomyopathy.